Great Lakes Advisors LLC Invests $812,000 in Stryker Corporation $SYK

Great Lakes Advisors LLC bought a new stake in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 2,579 shares of the medical technology company’s stock, valued at approximately $812,000.

Several other hedge funds have also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. bought a new stake in shares of Stryker in the 2nd quarter valued at approximately $25,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker during the 4th quarter worth approximately $26,000. Sankala Group LLC acquired a new stake in Stryker in the 4th quarter valued at $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter valued at $27,000. Finally, Atlas Capital Advisors Inc. bought a new stake in Stryker in the fourth quarter valued at $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Stock Performance

Shares of NYSE:SYK opened at $329.86 on Friday. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $396.86. The firm has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The business has a fifty day moving average of $326.99 and a 200-day moving average of $332.64.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the company earned $3.13 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts predict that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is 36.48%.

Analysts Set New Price Targets

SYK has been the subject of a number of analyst reports. Wolfe Research cut Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. Needham & Company LLC lowered their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Truist Financial increased their target price on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. Finally, Canaccord Genuity Group reduced their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 665,370 shares of company stock valued at $216,238,501 over the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.